Heart failure & cardiomyopathies
Initial Clinical Experience with Dapagliflozin in Addition to Optimized Medical Therapy in Paediatric Heart Failure Patients
Authors' conclusion
Dapagliflozin in addition to optimized HF therapy was safe and well tolerated in paediatric HF patients, with improvements in functional class, left ventricular contractility and heart failure symptoms.
Study context
- Population
- Paediatric heart failure (HF) patients (median age 9.0 years, range 0.2–17.1 years), April 2022 to February 2025
- Participants
- 37 patients
- Exposure
- Dapagliflozin added to optimized HF therapy
- Dapagliflozinn = 37
- Outcome
- Safety, clinical outcomes and adverse events
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
LVEF, GLS, HF classification, NT-proBNP · baseline to latest follow-up
- Left ventricular ejection fraction (LVEF) improved from 40% at baseline to 51% at 3-6 months and 57% at latest follow-up
- P = 0.016
- Global longitudinal strain (GLS) improved from −9.2% to −14.7% (baseline to latest follow-up)
- P = 0.023
- HF classification improved from baseline to latest follow-up
- P = 0.004
Observational data: associations, not effects.
Further findings
LVEF · baseline, 3-6 months, latest follow-up
- LVEF at baseline
- 40%
- LVEF at 3-6 months
- 51%
- LVEF at latest follow-up
- 57%
- Significant improvement
- P = 0.016
GLS · baseline to latest follow-up
- GLS at baseline
- −9.2%
- GLS at latest follow-up
- −14.7%
- Significant improvement
- P = 0.023
HF classification · baseline to latest follow-up
- Significant improvement
- P = 0.004
NT-proBNP · during follow-up
- Decreased, not statistically significant
Safety
Tolerability
- Well tolerated; no severe adverse effects observed
Clinical events during follow-up
- Ventricular assist device (VAD) implantation
- 4
- Heart transplantation
- 5
- Death
- 1
- VAD explanted due to myocardial recovery
- 6
Original publication
Initial Clinical Experience with Dapagliflozin in Addition to Optimized Medical Therapy in Paediatric Heart Failure Patients. ESC Heart Fail. Published 21 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →